Overview
- Name:
- Blinatumomab
- Description:
- Analog to the therapeutic Blinatumomab, also known as Blincyto. Blinatumomab is a BiTE directed to CD3 and CD19.
- Expression system:
- Mammalian
- Target:
- CD3 and CD19
- Isotype:
- BiTE (Bispecific T-cell Engager)
- Formulation:
- 0.01M PBS, pH 7.1-7.3
- Intended use:
- For research use only